Thrombocytopenia in liver disease

Current Opinion in Hematology

Volumn 15, Issue 5, 2008, Pages 473-480

  Giannini, Edoardo G ^a   Savarino, Vincenzo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Chronic liver disease; Cirrhosis; Hepatitis C virus; Hypersplenism; Interferon; Platelet antibodies; Thrombocytopenia

Indexed keywords

AKR 501; ANTIVIRUS AGENT; ELTROMBOPAG; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; ROMIPLOSTIM; THROMBOPOIETIN; BENZOIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; PYRAZOLE DERIVATIVE;

ANTIVIRAL THERAPY; BLOOD CLOTTING; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; LIVER TRANSPLANTATION; MEGAKARYOPOIESIS; PATHOPHYSIOLOGY; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SPLENECTOMY; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ARTIFICIAL EMBOLISM; LIVER DISEASE;

BENZOIC ACIDS; EMBOLIZATION, THERAPEUTIC; HUMANS; HYDRAZINES; LIVER DISEASES; PYRAZOLES; SPLENECTOMY; THROMBOCYTOPENIA;

EID: 55249090929     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32830a9746     Document Type: Review

References (46)

1. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2006; 23:1055-1065.
2. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000; 14 (Suppl D):60D-66D.
3. Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109:4607-4616.
4. Kaushansky K. Thrombopoietin: the primary regulator of megakaryocyte and platelet production. Thromb Haemost 1995; 74:521-525.
5. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of 'hypersplenic' thrombocytopenia. J Clin Invest 1966; 45:645-657.
6. Pereira J, Accatino L, Alfaro J, et al. Platelet autoantibodies in patients with chronic liver disease. Am J Hematol 1995; 50:173-178.
7. Pockros PJ, Duchini A, McMillan R, et al. Immune thrombocytopenic purpura in patients with chronic hepatitis C virus infection. Am J Gastroenterol 2002; 97:2040-2045.
8. Kajihara M, Okazaki Y, Kato S, et al. Evaluation of platelet kinetics in patients with liver cirrhosis: similarity to idiopathic thrombocytopenic purpura. J Gastroenterol Hepatol 2007; 22:112-118.
9. Koike Y, Yoneyama A, Shirai J, et al. Evaluation of thrombopoiesis in thrombocytopenic disorders by simultaneous measurement of reticulated platelets of whole blood and serum thrombopoietin concentrations. Thromb Haemost 1998; 79:1106-1110.
10. Panasiuk A, Prokopowicz D, Zak J, Panasiuk B. Reticulated platelets as a marker of megakaryopoiesis in liver cirrhosis; relation to thrombopoietin and hepatocyte growth factor serum concentrations. Hepatogastroenterology 2004; 51:1124-1128.
11. Christodoulou D, Christou L, Zervou E, et al. Antiplatelet antibodies in patients with chronic viral hepatitis receiving interferon-alpha. Hepatogastroenterology 2007; 54:1761-1765.
12. Panzer S, Seel E. Is there an increased frequency of autoimmune thrombocytopenia in hepatitis C infection? A review. Wien Med Wochenschr 2003; 153:417-420.
13. Panzer S, Seel E, Brunner M, et al. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol 2006; 77:513-517.
14. Kaushansky K. Thrombopoietin. N Engl J Med 1998; 339:746-754.
15. Martin TG, Somberg KA, Meng YG, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997; 127:285-288.
16. Peck-Radosavljevic M, Wichlas M, Zacherl J, et al. Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production. Blood 2000; 95:795-801.
17. Chatzipetrou MA, Tsaroucha AK, Weppler D, et al. Thrombocytopenia after liver transplantation. Transplantation 1999; 67:702-706.
18. Nascimbene A, Iannacone M, Brando B, De Gasperi A. Acute thrombocytopenia after liver transplant: role of platelet activation, thrombopoietin deficiency and response to high dose intravenous IgG treatment. J Hepatol 2007; 47:651-657.
19. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis 2002; 22:83-96.
20. Lisman T, Leebeek FWG, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol 2002; 37:280-287.
21. Mannucci PM. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? No. J Thromb Haemost 2006; 4:721-723.
22. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'. J Clin Invest 1996; 98:863-874.
23. Tripodi A, Salerno F, Chantarangkul V, et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41:553-558.
24. Tripodi A, Primignani M, Chantarangkul V, et al. Thrombin generation in patients with cirrhosis: the role of platelets. Hepatology 2006; 44:440-445.
25. el-Khishen MA, Henderson JM, Millikan WJ Jr, et al. Splenectomy is contraindicated for thrombocytopenia secondary to portal hypertension. Surg Gynecol Obstet 1985; 160:233-238.
26. Hayashi PH, Mehia C, Joachim Reimers H, et al. Splenectomy for thrombocytopenia in patients with hepatitis C cirrhosis. J Clin Gastroenterol 2006; 40:740-744.
27. Tashiro H, Itamoto T, Ohdan H, et al. Should splenectomy be performed for hepatitis C patients undergoing living-donor liver transplantation? J Gastreonterol Hepatol 2007; 22:959-960.
28. Lee CM, Leung TK, Wang HJ, et al. Evaluation of the effect of partial splenic embolization on platelet values for liver cirrhosis patients with thrombocytopenia. World J Gastroenterol 2007; 13:619-622.
29. Maddison F. Embolic therapy of hypersplenism. Invest Radiol 1973; 8:280-281.
30. Sangro B, Bilbao I, Herrero I, et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology 1993; 18:309-314.
31. Hayashi H, Beppu T, Masuda T, et al. Predictive factors for platelet increase after partial splenic embolization in liver cirrhosis patients. J Gastroenterol Hepatol 2007; 22:1638-1642.
32. Porter BA, Frey CF, Link DP, et al. Splenic embolization monitored by the video dilution technique. Am J Roentgenol 1985; 141:1063-1065.
33. Sezai S, Kamisaka K, Ikegami F, et al. Regulation of hepatic thrombopoietin production by portal hemodynamics in liver cirrhosis. Am J Gastroenterol 1998; 93:80-82.
34. Hidaka H, Kokubu S, Saigenji K, et al. Restoration of thrombopoietin production after partial splenic embolization leads to resolution of thrombocytopenia in liver cirrhosis. Hepatol Res 2002; 23:265-273.
35. Giannini E, Botta F, Borro P, et al. Relationship between thrombopoietin serum levels and liver function in patients with chronic liver disease related to hepatitis C virus infection. Am J Gastroenterol 2003; 98:2516-2520.
36. Dessypris E, Graber SE, Krantz SB, Stone WJ. Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 1988; 72:2060-2062.
37. Pirisi M, Fabris C, Soardo G, et al. Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment. J Hepatol 1994; 21:376-380.
38. Homoncik M, Jilma-Stohlawetz P, Schmid M, et al. Erythropoietin increases platelet reactivity and platelet counts in patients with alcoholic liver cirrhosis: a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2004; 20:437-443.
39. Homoncik M, Sieghart W, Formann E, et al. Erythropoietin treatment is associated with more severe thrombocytopenia in patients with chronic hepatitis C undergoing antiviral therapy. Am J Gastroenterol 2006; 101:2275-2282.
40. Ghalib R, Levine C, Hassan M, et al. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37:1165-1171.
41. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-3248.
42. Kuter DJ. Whatever happened to thrombopoietin? Transfusion 2002; 42:279-283.
43. Evangelista ML, Amadori S, Stasi R. Biologic aspects of thrombopoietin and the development of novel thrombopoietic agents for clinical use. Curr Drug Discov Technol 2007; 4:162-173.
44. Jenkins JM, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739-4741.
45. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007; 357:2227-2236.
46. Afdhal NH, McHutchison JG. Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection. Aliment Pharmacol Ther 2007; 26 (Suppl1):29-39.